7) V2: 3.2 (1.1-3.9) V3: 2.2 (1.2-3.4) t max V1: 1, pp.2-6 ,
27) MPA MPAG AcMPAG DN-AUC 0-12 18, pp.152-909 ,
119] 7 patients 50±10 years 4.4±3.9 years (0.3-11.5) Steady-state, 1-3 g/day 2.4±0.9 g/day (35.5±14.1 mg/kg/day) r² C 0 -AUC0 -12 = 0.714; r² C 2 -AUC 0-12 = 0.663; r² C 8 -AUC 0-12 = 0.884 ; otherwise, r² = 0.176-0.732 Recommended sparse sampling algorithms: ? log ,
Cystic fibrosis ? D: Dose ? HTx: Heart transplantation ? KTx: Kidney transplantation ? LTx: Lung transplantation ? N/R: not reported ,
Use of cyclosporine in thoracic transplantation, Transplantation Proceedings, vol.36, issue.2, pp.331-336, 2004. ,
DOI : 10.1016/j.transproceed.2004.01.024
Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.769-781, 2007. ,
DOI : 10.1016/j.healun.2007.06.004
Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart???Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.782-795, 2007. ,
DOI : 10.1016/j.healun.2007.06.003
Monitoring C2 Level Predicts Exposure in Maintenance Lung Transplant Patients Receiving the Microemulsion Formulation of Cyclosporine (Neoral), The Journal of Heart and Lung Transplantation, vol.24, issue.8, pp.1076-1080, 2005. ,
DOI : 10.1016/j.healun.2003.05.002
Mycophenolate Mofetil Dose Reduction for Gastrointestinal Intolerance is Associated With Increased Rates of Rejection in Heart Transplant Patients, The Journal of Heart and Lung Transplantation, vol.27, issue.1, pp.72-77, 2008. ,
DOI : 10.1016/j.healun.2007.10.012
Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation, Clinical Transplantation, vol.27, issue.0, pp.35-40, 2008. ,
DOI : 10.1097/00007890-199907150-00011
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria, The Journal of Heart and Lung Transplantation, vol.21, issue.3, pp.297-310, 2002. ,
DOI : 10.1016/S1053-2498(02)00398-4
Immunosuppressive therapy after human lung transplantation, European Respiratory Journal, vol.23, issue.1, pp.159-171, 2004. ,
DOI : 10.1183/09031936.03.00039203
Immunosuppression for Lung Transplantation, Drugs, vol.22, issue.11, pp.1531-1539, 2007. ,
DOI : 10.2165/00003495-200767110-00002
CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED TO TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS, Transplantation, vol.67, issue.7, pp.1839-1842, 1999. ,
DOI : 10.1097/00007890-199904150-00100
The Role of Therapeutic Drug Monitoring in Individualizing Immunosuppressive Drug Therapy: Recent Developments, Therapeutic Drug Monitoring, vol.28, issue.6, pp.720-725, 2006. ,
DOI : 10.1097/FTD.0b013e31802c5cf5
NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVE, Transplantation, vol.68, issue.1, pp.55-62, 1999. ,
DOI : 10.1097/00007890-199907150-00011
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation, Clinical Pharmacology and Therapeutics, vol.54, issue.2, pp.205-218, 1993. ,
DOI : 10.1038/clpt.1993.132
C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation, BioDrugs, vol.1, issue.51, pp.279-290, 2001. ,
DOI : 10.2165/00063030-200115050-00001
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-2503, 2007. ,
DOI : 10.1097/00007691-200412000-00005
Post-surgical and obstructive gastroparesis, Current Gastroenterology Reports, vol.98, issue.4, pp.280-285, 2007. ,
DOI : 10.1007/s11894-007-0031-2
Gastroparesis After Combined Heart and Lung Transplantation, Journal of Clinical Gastroenterology, vol.34, issue.1, pp.34-39, 2002. ,
DOI : 10.1097/00004836-200201000-00007
Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors, The Journal of Heart and Lung Transplantation, vol.20, issue.4, pp.431-438, 2001. ,
DOI : 10.1016/S1053-2498(00)00234-5
Association Between Cyclosporine Concentrations at 2 Hours Post-dose and Clinical Outcomes in De Novo Lung Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2120-2128, 2005. ,
DOI : 10.1016/j.healun.2005.05.005
A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients, The Journal of Heart and Lung Transplantation, vol.21, issue.9, pp.1016-1021, 2002. ,
DOI : 10.1016/S1053-2498(02)00419-9
Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction, Clinical Transplantation, vol.2, issue.2, pp.144-150, 2003. ,
DOI : 10.1097/00007691-200108000-00001
Noeral C-2 monitoring in cardiac transplant patients, Transplantation Proceedings, vol.33, issue.1-2, pp.1572-1575, 2001. ,
DOI : 10.1016/S0041-1345(00)02598-7
Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation, Pharmacotherapy, vol.18, issue.4, pp.847-850, 1998. ,
Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions, Transplantation, vol.76, issue.4, pp.683-688, 2003. ,
DOI : 10.1097/01.TP.0000076473.71399.26
Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis, Transplantation Proceedings, vol.29, issue.5, pp.2450-2453, 1997. ,
DOI : 10.1016/S0041-1345(97)00446-6
Altered Pharmacokinetics of Cyclosporin in Heart-Lung Transplant Recipients with Cystic Fibrosis, Therapeutic Drug Monitoring, vol.12, issue.6, pp.520-524, 1990. ,
DOI : 10.1097/00007691-199011000-00002
Randomized, Trough Blood Cyclosporine Concentration-controlled Trial to Compare the Pharmacodynamics of Sandimmune and Neoral in De Novo Lung Transplant Recipients, Therapeutic Drug Monitoring, vol.21, issue.1, pp.17-26, 1999. ,
DOI : 10.1097/00007691-199902000-00004
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, Pharmacological Research, vol.43, issue.6, pp.547-551, 2001. ,
DOI : 10.1006/phrs.2001.0823
Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring, The Journal of Heart and Lung Transplantation, vol.25, issue.10, pp.1223-1229, 2006. ,
DOI : 10.1016/j.healun.2006.07.002
Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC0???12 monitoring in cardiac transplant recipients over the first year post-transplantation, European Journal of Clinical Pharmacology, vol.66, issue.12, pp.813-820, 2003. ,
DOI : 10.1007/s002280050718
Bayesian Forecasting of Oral Cyclosporin Pharmacokinetics in Stable Lung Transplant Recipients With and Without Cystic Fibrosis, Therapeutic Drug Monitoring, vol.25, issue.1, pp.28-35, 2003. ,
DOI : 10.1097/00007691-200302000-00004
NONMEM Population Pharmacokinetic Modeling of Orally Administered Cyclosporine From Routine Drug Monitoring Data After Heart Transplantation, Therapeutic Drug Monitoring, vol.20, issue.3, pp.284-293, 1998. ,
DOI : 10.1097/00007691-199806000-00008
Population Pharmacokinetics of Cyclosporine in Cardiopulmonary Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.2, pp.116-122, 2005. ,
DOI : 10.1097/01.ftd.0000148448.51225.2c
REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2, Transplantation, vol.59, issue.4, pp.505-511, 1995. ,
DOI : 10.1097/00007890-199559040-00011
Pharmacokinetic validation of neoral absorption profiling, Transplantation Proceedings, vol.32, issue.3, pp.53-56, 2000. ,
DOI : 10.1016/S0041-1345(00)00864-2
Letter to the Editor, Therapeutic Drug Monitoring, vol.28, issue.1, p.138, 2006. ,
DOI : 10.1097/01.ftd.0000188016.36982.35
Application of a Gamma Model of Absorption to Oral Cyclosporin, Clinical Pharmacokinetics, vol.16, issue.5, pp.375-382, 2001. ,
DOI : 10.2165/00003088-200140050-00004
Effect of Pravastatin on Outcomes after Cardiac Transplantation, New England Journal of Medicine, vol.333, issue.10, pp.621-627, 1995. ,
DOI : 10.1056/NEJM199509073331003
Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients, British Journal of Clinical Pharmacology, vol.44, issue.6, pp.537-542, 1997. ,
DOI : 10.1046/j.1365-2125.1997.t01-1-00625.x
Effect of Metabolic Inhibitors on Cyclosporine Pharmacokinetics Using a Population Approach, Therapeutic Drug Monitoring, vol.20, issue.4, pp.390-395, 1998. ,
DOI : 10.1097/00007691-199808000-00007
Registry of the International Society for Heart and Lung Transplantation: Tenth Official Pediatric Lung and Heart/Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.12, pp.1223-1228, 2007. ,
DOI : 10.1016/j.healun.2007.07.035
Immunosuppressive Therapy for Paediatric Transplant Patients, Clinical Pharmacokinetics, vol.30, issue.6, pp.115-135, 2002. ,
DOI : 10.2165/00003088-200241020-00004
Developmental pharmacology-drug disposition, action, and therapy in infants and children, N Engl J Med, vol.349, issue.12, pp.1157-1167, 2003. ,
Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations, Clinical Pharmacokinetics, vol.67, issue.6, pp.1077-1097, 2006. ,
DOI : 10.2165/00003088-200645110-00003
Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants, Clin Chem, vol.34, issue.10, pp.2012-2015, 1988. ,
Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome, Clinical Pharmacology and Therapeutics, vol.53, issue.5 ,
DOI : 10.1038/clpt.1993.68
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics., British Journal of Clinical Pharmacology, vol.9, issue.2, pp.247-256, 1982. ,
DOI : 10.1111/j.1365-2125.1982.tb01969.x
An investigation of the pharmacokinetics, toxicity, and clinical efficacy of neoral cyclosporin in cystic fibrosis patients, Transplantation Proceedings, vol.29, issue.1-2, pp.599-601, 1997. ,
DOI : 10.1016/S0041-1345(96)00319-3
Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis, European Journal of Clinical Pharmacology, vol.48, issue.3-4, pp.3-4, 1995. ,
DOI : 10.1007/BF00198313
A Randomized, Controlled Trial of C0- Vs C2-guided Therapeutic Drug Monitoring of Cyclosporine in Stable Heart Transplant Patients, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2137-2143, 2005. ,
DOI : 10.1016/j.healun.2005.04.019
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice, Clinical Therapeutics, vol.24, issue.3, pp.330-350, 2002. ,
DOI : 10.1016/S0149-2918(02)85038-X
Methods for Clinical Monitoring of Cyclosporin in Transplant Patients, Clinical Pharmacokinetics, vol.25, issue.5, pp.427-447, 2000. ,
DOI : 10.2165/00003088-200038050-00004
Cyclosporine Monitoring With 2-Hour Postdose Levels in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.4, pp.417-421, 2005. ,
DOI : 10.1097/01.ftd.0000159786.10625.85
Advantages of C2 Monitoring to Avoid Acute Rejection in Pediatric Heart Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.25, issue.6, pp.619-625, 2006. ,
DOI : 10.1016/j.healun.2006.02.002
Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy, Clin Transplant, 1998. ,
Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors, The Journal of Heart and Lung Transplantation, vol.22, issue.7, pp.715-722, 2003. ,
DOI : 10.1016/S1053-2498(02)00649-6
Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients, Clin Transplant, vol.11, issue.5, pp.399-405, 1997. ,
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients, Clin Chem, vol.47, issue.9, pp.1679-1687, 2001. ,
The temporal profile of calcineurin inhibition by cyclosporine in vivo, Transplantation Nov, vol.15, issue.689, pp.1356-1361, 1999. ,
Challenges in Cyclosporine Therapy: The Role of Therapeutic Monitoring by Area Under the Curve Monitoring, Therapeutic Drug Monitoring, vol.17, issue.6, 1995. ,
DOI : 10.1097/00007691-199512000-00013
A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3, Transplantation, vol.62, issue.12, pp.1744-1752, 1996. ,
DOI : 10.1097/00007890-199612270-00009
Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study, J Am Soc Nephrol, 2001. ,
Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy, Clin Chem, vol.37, issue.11, pp.1905-1908, 1991. ,
A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.20, issue.8, pp.897-900, 2001. ,
DOI : 10.1016/S1053-2498(01)00272-8
Some suggestions for measuring predictive performance, Journal of Pharmacokinetics and Biopharmaceutics, vol.61, issue.4, pp.503-512, 1981. ,
DOI : 10.1007/BF01060893
Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration???Time Curve: Review of Current Algorithms, Therapeutic Drug Monitoring, vol.23, issue.2, pp.100-114, 2001. ,
DOI : 10.1097/00007691-200104000-00003
Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal Transplants, Clinical Pharmacokinetics, vol.17, issue.1, pp.71-80, 2002. ,
DOI : 10.2165/00003088-200241010-00006
Population Pharmacokinetic Modeling of Oral Cyclosporin Using NONMEM, Therapeutic Drug Monitoring, vol.26, issue.1, pp.23-30, 2004. ,
DOI : 10.1097/00007691-200402000-00006
Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients, British Journal of Clinical Pharmacology, vol.32, issue.1, pp.18-27, 2005. ,
DOI : 10.1097/01.TP.0000089006.00653.64
Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients, Therapeutic Drug Monitoring, vol.29, issue.1, pp.96-102, 2007. ,
DOI : 10.1097/FTD.0b013e3180310f9d
Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model, European Journal of Clinical Pharmacology, vol.56, issue.6-7, pp.6-7, 2000. ,
DOI : 10.1007/s002280000164
Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen, J Heart Lung Transplant, vol.17, issue.9, pp.849-853, 1998. ,
Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection?, J Heart Lung Transplant, vol.16, issue.3, pp.268-274, 1997. ,
Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients, Clin Chem, vol.36, issue.8, pp.1474-1478, 1990. ,
Blood Cyclosporin Concentrations but Not Doses Correlate with Acute Changes in Renal Function Following Heart and Heart-Lung Transplantation, Therapeutic Drug Monitoring, vol.14, issue.4, pp.275-280, 1992. ,
DOI : 10.1097/00007691-199208000-00003
Relationship Between Pharmacokinetic Parameters of Cyclosporin and the Incidence of Acute Rejection After Heart Transplantation, Transplantation Proceedings, vol.37, issue.9, pp.4014-4017, 2005. ,
DOI : 10.1016/j.transproceed.2005.09.149
Blood cyclosporine C0 and C2 concentrations and cytomegalovirus infections following lung transplantation, Transplantation Proceedings, vol.35, issue.5, pp.1992-1993, 2003. ,
DOI : 10.1016/S0041-1345(03)00689-4
Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation., British Journal of Clinical Pharmacology, vol.319, issue.2, pp.513-520, 1992. ,
DOI : 10.1111/j.1365-2125.1992.tb05657.x
Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1, Transplantation, vol.73, issue.6 ,
DOI : 10.1097/00007890-200203270-00022
Efficacy and Safety Outcomes Among De Novo Renal Transplant Recipients Managed by C2 Monitoring of Cyclosporine A Microemulsion: Results of a 12-Month, Randomized, Multicenter Study, Transplantation, vol.79, issue.5, pp.577-583, 2005. ,
DOI : 10.1097/01.TP.0000153158.91683.34
Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion, Transplantation, vol.76, issue.6, pp.903-908, 2003. ,
DOI : 10.1097/01.TP.0000089006.00653.64
C2 monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses, Transplantation Proceedings, vol.34, issue.8, 2002. ,
DOI : 10.1016/S0041-1345(02)03699-0
C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients, Transplant International, vol.35, issue.1, 2005. ,
DOI : 10.1097/00007890-199802270-00009
Monitoring of Cyclosporine 2-Hour Post-Dose Levels in Heart Transplantation: Improvement in Clinical Outcomes, The Journal of Heart and Lung Transplantation, vol.24, issue.9, pp.1343-1346, 2005. ,
DOI : 10.1016/j.healun.2004.08.002
Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation, The Journal of Heart and Lung Transplantation, vol.23, issue.10, pp.1170-1174, 2004. ,
DOI : 10.1016/j.healun.2003.08.032
Cyclosporine C2 Target Levels and Acute Cellular Rejection After Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.8, pp.928-934, 2006. ,
DOI : 10.1016/j.healun.2006.03.020
Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction, Transplantation Proceedings, vol.32, issue.2, pp.446-448, 2000. ,
DOI : 10.1016/S0041-1345(00)00842-3
Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C2) in heart transplant patients receiving anti-thymocyte globulin induction, Clinical Transplantation, vol.6, issue.2, pp.148-151, 2004. ,
DOI : 10.1097/00007890-200101150-00012
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction, Transplantation, 2008. ,
Enhanced clinical utility of De Novo cyclosporine C2 monitoring after lung transplantation, The Journal of Heart and Lung Transplantation, vol.23, issue.9, 2004. ,
DOI : 10.1016/j.healun.2003.08.008
C2 and C0 Values for Monitoring Cyclosporine Therapy in Stable Heart Transplant Recipients, Transplantation Proceedings, vol.37, issue.2, pp.1355-1359, 2005. ,
DOI : 10.1016/j.transproceed.2005.01.079
New immunosuppressive regimens in lung transplantation, European Respiratory Journal, vol.10, issue.11, pp.2630-2637, 1997. ,
DOI : 10.1183/09031936.97.10112630
Suggested guidelines for the use of tacrolimus in cardiac transplant recipients, The Journal of Heart and Lung Transplantation, vol.20, issue.7, pp.734-738, 2001. ,
DOI : 10.1016/S1053-2498(00)00222-9
Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols, The Journal of Heart and Lung Transplantation, vol.20, issue.5, pp.511-517, 2001. ,
DOI : 10.1016/S1053-2498(01)00244-3
Overview of tacrolimus-based immunosuppression after heart or lung transplantation, The Journal of Heart and Lung Transplantation, vol.24, issue.2, pp.119-130, 2005. ,
DOI : 10.1016/j.healun.2004.02.022
Suggested guidelines for the use of tacrolimus in lung-transplant recipients, J Heart Lung Transplant, vol.18, issue.3, pp.175-176, 1999. ,
OPTIMIZATION OF THE IMMUNOSUPPRESSIVE PROTOCOL AFTER LUNG TRANSPLANTATION1, Transplantation, vol.68, issue.1, pp.67-71, 1999. ,
DOI : 10.1097/00007890-199907150-00013
Factors Affecting the Pharmacokinetics of Tacrolimus in the First Year After Renal Transplantation, Transplantation Proceedings, vol.30, issue.4, pp.1261-1263, 1998. ,
DOI : 10.1016/S0041-1345(98)00234-6
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation, Clinical Pharmacokinetics, vol.33, issue.3, pp.623-53, 2004. ,
DOI : 10.2165/00003088-200443100-00001
Clinical Pharmacokinetics of Tacrolimus in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.21, issue.1, pp.2-7, 1999. ,
DOI : 10.1097/00007691-199902000-00002
Pharmacokinetics of tacrolimus in heart transplantation, Transplantation Proceedings, vol.34, issue.5, pp.1836-1838, 2002. ,
DOI : 10.1016/S0041-1345(02)03097-X
Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: A comparison with cyclosporine neoral, Transplantation Proceedings, vol.36, issue.8, pp.2386-2387, 2004. ,
DOI : 10.1016/j.transproceed.2004.08.053
Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation, Transplantation Proceedings, vol.36, issue.8, pp.2388-2389, 2004. ,
DOI : 10.1016/j.transproceed.2004.06.037
Factors Affecting the Pharmacokinetics of Tacrolimus in the First Year After Renal Transplantation, Transplantation Proceedings, vol.30, issue.4, pp.1261-1263, 1998. ,
DOI : 10.1016/S0041-1345(98)00234-6
Is Microparticle Enzyme-Linked Immunoassay (MEIA) Reliable for Use in Tacrolimus TDM? Comparison of MEIA to Liquid Chromatography With Mass Spectrometric Detection Using Longitudinal Trough Samples From Transplant Recipients, Therapeutic Drug Monitoring, vol.28, issue.4, pp.491-504, 2006. ,
DOI : 10.1097/00007691-200608000-00003
Low Hematocrit and Serum Albumin Concentrations Underlie the Overestimation of Tacrolimus Concentrations by Microparticle Enzyme Immunoassay versus Liquid Chromatography-Tandem Mass Spectrometry, Clinical Chemistry, vol.51, issue.3, pp.586-592, 2005. ,
DOI : 10.1373/clinchem.2004.043950
Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring, Transplantation Proceedings, vol.35, issue.5, pp.1988-1991, 2003. ,
DOI : 10.1016/S0041-1345(03)00656-0
Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions, American Journal of Transplantation, vol.43, issue.6, pp.1477-1482, 2005. ,
DOI : 10.1097/00007890-200205151-00003
Tacrolimus pharmacokinetics in heart transplant, Transplantation Proceedings, vol.34, issue.1, pp.142-143, 2002. ,
DOI : 10.1016/S0041-1345(01)02706-3
Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1328, 2005. ,
DOI : 10.2165/00003088-200544120-00010
Cytochrome P450 3A4 and P-glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea, American Journal of Transplantation, vol.16, issue.6 ,
DOI : 10.1177/00912700122009999
Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation, The Journal of Heart and Lung Transplantation, vol.21, issue.1, p.144, 2002. ,
DOI : 10.1016/S1053-2498(01)00682-9
Pharmacokinetics of tacrolimus during the early phase after heart transplantation, Transplantation Proceedings, vol.33, issue.3, pp.2386-2389, 2001. ,
DOI : 10.1016/S0041-1345(01)02032-2
Itraconazole Prophylaxis in Lung Transplant Recipients Receiving Tacrolimus (FK 506): Efficacy and Drug Interaction, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2148-2152, 2005. ,
DOI : 10.1016/j.healun.2005.05.003
Clinical Use and Bioavailability of Tacrolimus in Heart-Lung and Double Lung Transplant Recipients With Cystic Fibrosis, Transplantation Proceedings, vol.30, issue.4, pp.1519-1520, 1998. ,
DOI : 10.1016/S0041-1345(98)00341-8
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients, Clinical Pharmacokinetics, vol.18, issue.2, pp.13-58, 2007. ,
DOI : 10.2165/00003088-200746010-00002
Pharmacokinetics and Protein Binding of Mycophenolic Acid in Stable Lung Transplant Recipients, Therapeutic Drug Monitoring, vol.24, issue.2, pp.310-314, 2002. ,
DOI : 10.1097/00007691-200204000-00013
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation, Therapeutic Drug Monitoring, vol.28, issue.2, pp.145-154, 2006. ,
DOI : 10.1097/01.ftd.0000199358.80013.bd
Therapeutic Mycophenolic Acid Monitoring by Means of Limited Sampling Strategy in Orthotopic Heart Transplant Patients, Transplantation Proceedings, vol.37, issue.5, pp.2240-2243, 2005. ,
DOI : 10.1016/j.transproceed.2005.03.090
Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.3, pp.315-321, 2005. ,
DOI : 10.1097/01.ftd.0000163949.40686.0f
Mycophenolate Mofetil Pharmacokinetics in Transplant Patients Receiving Cyclosporine or Tacrolimus in Combination Therapy, Pharmacology & Toxicology, vol.87, issue.4, pp.182-184, 2000. ,
DOI : 10.1034/j.1600-0773.2000.pto870407.x
Mycophenolate Pharmacokinetics in Early Period Following Lung or Heart Transplantation, Annals of Pharmacotherapy, vol.50, issue.12, pp.1761-1767, 2003. ,
DOI : 10.1038/clpt.1993.68
Immunosuppression: practice and trends, American Journal of Transplantation, vol.76, issue.4, pp.38-53, 2004. ,
DOI : 10.1111/j.1600-6135.2004.00397.x
Mycophenolic Acid Plasma Concentrations: Influence of Comedication, Therapeutic Drug Monitoring, vol.23, issue.1, pp.35-38, 2001. ,
DOI : 10.1097/00007691-200102000-00007
Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.5, pp.517-525, 2005. ,
DOI : 10.1016/j.healun.2005.02.002
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1, Transplantation, vol.66, issue.4, pp.507-515, 1998. ,
DOI : 10.1097/00007890-199808270-00016
Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring, The Journal of Heart and Lung Transplantation, vol.18, issue.2, pp.143-149, 1999. ,
DOI : 10.1016/S1053-2498(98)00002-3
Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.3, pp.282-291, 2008. ,
DOI : 10.1097/FTD.0b013e318166eba0
Value of mycophenolic acid trough level monitoring after lung transplantation, Transplantation Proceedings, vol.34, issue.5, pp.1881-1883, 2002. ,
DOI : 10.1016/S0041-1345(02)03107-X
Mycophenolic acid concentrations are associated with cardiac allograft rejection, The Journal of Heart and Lung Transplantation, vol.19, issue.11, pp.1071-1076, 2000. ,
DOI : 10.1016/S1053-2498(00)00191-1
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients, Clinical Biochemistry, vol.34, issue.1, pp.17-22, 2001. ,
DOI : 10.1016/S0009-9120(00)00184-3
A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A???Containing and cyclosporin A???Free immunosuppressive regimens, Clinical Therapeutics, vol.28, issue.6, 2006. ,
DOI : 10.1016/j.clinthera.2006.06.015
Best Single Time Points to Predict the Area-Under-the-Curve in Long-Term Heart Transplant Patients Taking Mycophenolate Mofetil in Combination with Cyclosporine or Tacrolimus, The Journal of Heart and Lung Transplantation, vol.24, issue.10, pp.1614-1618, 2005. ,
DOI : 10.1016/j.healun.2004.12.112
Lack of Correlation Between MMF Dose and MPA Level in Pediatric and Young Adult Cardiac Transplant Patients: Does the MPA Level Matter?1, American Journal of Transplantation, vol.48, issue.9, pp.1495-1500, 2004. ,
DOI : 10.1177/00912700022009143
Time points predictors of cyclosporine microemulsion and of mycophenolic acid area-under-the-curve (0-12 hr) in long-term heart transplant patients, Am J Transplant, vol.3, issue.S5, p.168, 2003. ,
Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients, Pharmacotherapy, vol.19, issue.9, pp.1232-1240, 2006. ,
DOI : 10.2165/00003088-200241050-00001
THE IMPACT OF ROUTINE MYCOPHENOLATE MOFETIL DRUG MONITORING ON THE TREATMENT OF CARDIAC ALLOGRAFT REJECTION, Transplantation, vol.69, issue.11, pp.2326-2330, 2000. ,
DOI : 10.1097/00007890-200006150-00018
Clinical Pharmacokinetics of Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.34, issue.6, pp.429-455, 1998. ,
DOI : 10.2165/00003088-199834060-00002
A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-847, 2005. ,
DOI : 10.2165/00003088-200544080-00005
Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.22, issue.5, pp.587-590, 2003. ,
DOI : 10.1016/S1053-2498(02)01159-2
Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma, Journal of Chromatography B, vol.852, issue.1-2, pp.674-678, 2007. ,
DOI : 10.1016/j.jchromb.2007.02.038
IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM, Drug Metabolism and Disposition, vol.33, issue.1, pp.139-146, 2005. ,
DOI : 10.1124/dmd.104.001651
Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil, British Journal of Pharmacology, vol.350, issue.5, pp.1075-1082, 1999. ,
DOI : 10.1038/sj.bjp.0702399
Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes, British Journal of Pharmacology, vol.21, issue.5, pp.1027-1034, 2001. ,
DOI : 10.1038/sj.bjp.0703898
Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5, Therapeutic Drug Monitoring, vol.26, issue.6, pp.600-608, 2004. ,
DOI : 10.1097/00007691-200412000-00004
Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil, Clin Chem, vol.45, issue.3, pp.419-422, 1999. ,
Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients, Therapeutic Drug Monitoring, vol.25, issue.3, pp.407-414, 2003. ,
DOI : 10.1097/00007691-200306000-00025
Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients, Therapeutic Drug Monitoring, vol.24, issue.3, pp.390-399, 2002. ,
DOI : 10.1097/00007691-200206000-00011
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings, Transplant Immunology, vol.5, issue.3, pp.225-232, 1997. ,
DOI : 10.1016/S0966-3274(97)80042-1
Tacrolimus or Cyclosporine: Which Is the Better Partner for Mycophenolate Mofetil in Heart Transplant Recipients?, Transplantation, vol.78, issue.4, pp.591-598, 2004. ,
DOI : 10.1097/01.TP.0000129814.52456.25
Tacrolimus/mycophenolate mofetil vs cyclosporine/mycophenolate mofetil: comparison of mycophenolate acid trough levels and coronary vasomotor function, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.191, 2001. ,
DOI : 10.1016/S1053-2498(00)00398-3
Evidence That Tacrolimus Augments the Bioavailability of Mycophenolate Mofetil Through the Inhibition of Mycophenolic Acid Glucuronidation, Therapeutic Drug Monitoring, vol.21, issue.1, pp.35-43, 1999. ,
DOI : 10.1097/00007691-199902000-00006
Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study, Nephrology Dialysis Transplantation, vol.14, issue.3, pp.706-708, 1999. ,
DOI : 10.1093/ndt/14.3.706
Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid, Therapeutic Drug Monitoring, vol.23, issue.2, 2001. ,
DOI : 10.1097/00007691-200104000-00005
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation, Kidney International, vol.62, issue.3, pp.1060-1067, 2002. ,
DOI : 10.1046/j.1523-1755.2002.00531.x
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation, Kidney International, vol.62, issue.3, pp.1060-1067, 2002. ,
DOI : 10.1046/j.1523-1755.2002.00531.x
Pharmacokinetics of Mycophenolate Mofetil and Sirolimus in Children, Therapeutic Drug Monitoring, vol.30, issue.2, pp.138-142, 2008. ,
DOI : 10.1097/FTD.0b013e31816ba73a
Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil, The Journal of Heart and Lung Transplantation, vol.20, issue.10, pp.1035-1043, 2001. ,
DOI : 10.1016/S1053-2498(01)00305-9
Pharmacokinetics of Mycophenolic Acid and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients, Annals of Pharmacotherapy, vol.28, issue.9, pp.1509-1516, 2006. ,
DOI : 10.1345/aph.1H149
Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12, pp.1675-1685, 2008. ,
DOI : 10.1097/TP.0b013e3181744199
Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection, Clinical Transplantation, vol.87, issue.3, pp.196-201, 2002. ,
DOI : 10.1097/00007691-200104000-00005
Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients, Clinical Therapeutics, vol.30, issue.4, pp.673-683, 2008. ,
DOI : 10.1016/j.clinthera.2008.04.014
The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels, Transplantation Proceedings, vol.31, issue.1-2, pp.84-87, 1999. ,
DOI : 10.1016/S0041-1345(98)01448-1
A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1, Transplantation, vol.68, issue.2, pp.261-266, 1999. ,
DOI : 10.1097/00007890-199907270-00018
Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.PAP, issue.4, pp.419-427, 2008. ,
DOI : 10.1097/FTD.0b013e31817d7064
Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods, Therapeutic Drug Monitoring, vol.27, issue.3, pp.354-361, 2005. ,
DOI : 10.1097/01.ftd.0000162231.90811.38
Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients, Clinical Pharmacokinetics, vol.20, issue.6, pp.253-266, 2004. ,
DOI : 10.2165/00003088-200443040-00004
The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation, Transplantation Proceedings, vol.33, issue.3, pp.2163-2164, 2001. ,
DOI : 10.1016/S0041-1345(01)01927-3
Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue, PROTEOMICS, vol.4, issue.9, 2004. ,
DOI : 10.1002/pmic.200300836
The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, Transplantation Proceedings, vol.33, issue.1-2, pp.1080-1081, 2001. ,
DOI : 10.1016/S0041-1345(00)02424-6
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients, Clinical Pharmacology & Therapeutics, vol.75, issue.5, 2004. ,
DOI : 10.1016/j.clpt.2003.12.009
Promise of neoral C2, basiliximab, and everolimus in lung transplantation, Transplantation Proceedings, vol.36, issue.2, pp.509-513, 2004. ,
DOI : 10.1016/j.transproceed.2004.01.045
Sirolimus, Clinical Pharmacokinetics, vol.14, issue.12, pp.769-786, 2005. ,
DOI : 10.2165/00003088-200544080-00001
Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation, The Journal of Heart and Lung Transplantation, vol.22, issue.2, pp.210-213, 2003. ,
DOI : 10.1016/S1053-2498(02)00564-8
Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation, Transplantation, vol.75, issue.9, 2003. ,
DOI : 10.1097/01.TP.0000064083.02120.2C
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation, The Journal of Heart and Lung Transplantation, vol.27, issue.2, pp.141-149, 2008. ,
DOI : 10.1016/j.healun.2007.08.014
Apparent Clearance of Sirolimus in Heart Transplant Recipients: Impact of Primary Diagnosis and Serum Lipids, Therapeutic Drug Monitoring, vol.28, issue.6, pp.614-622, 2006. ,
DOI : 10.1097/01.ftd.0000246765.05248.fa
Clinical Pharmacokinetics of Sirolimus, Clinical Pharmacokinetics, vol.33, issue.8, pp.573-585, 2001. ,
DOI : 10.2165/00003088-200140080-00002
Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years: A Randomized Clinical Trial, Circulation, vol.110, issue.17, pp.2694-2700, 2004. ,
DOI : 10.1161/01.CIR.0000136812.90177.94
De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow-Up Analysis, Transplantation Proceedings, vol.37, issue.5, pp.2231-2239, 2005. ,
DOI : 10.1016/j.transproceed.2005.03.086
Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure, Transplantation, vol.77, issue.4, pp.568-574, 2004. ,
DOI : 10.1097/01.TP.0000103740.98095.14
The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin), J Clin Pharmacol, vol.39, issue.11, pp.1155-1161, 1999. ,
Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients, Clinical Pharmacokinetics, vol.44, issue.11, pp.1135-1148, 2006. ,
DOI : 10.2165/00003088-200645110-00007
Exposure-response relationships and drug interactions of sirolimus, The AAPS Journal, vol.6, issue.4, p.28, 2004. ,
DOI : 10.1208/aapsj060428
The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation, Therapeutic Drug Monitoring, vol.27, issue.5, pp.666-676, 2005. ,
DOI : 10.1097/01.ftd.0000175911.70172.2e
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients, New England Journal of Medicine, vol.349, issue.9, pp.847-858, 2003. ,
DOI : 10.1056/NEJMoa022171
Everolimus Versus Azathioprine in Maintenance Lung Transplant Recipients: An International, Randomized, Double-Blind Clinical Trial, American Journal of Transplantation, vol.55, issue.1, pp.169-177, 2006. ,
DOI : 10.1016/j.healun.2003.08.008
Clinical Pharmacokinetics of Everolimus, Clinical Pharmacokinetics, vol.33, issue.2, pp.83-95, 2004. ,
DOI : 10.2165/00003088-200443020-00002
Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady-State Pharmacokinetics, The Journal of Clinical Pharmacology, vol.73, issue.suppl. 1, pp.141-147, 2003. ,
DOI : 10.1177/0091270002239822
Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications, Clinical Pharmacology & Therapeutics, vol.70, issue.3, pp.247-254, 2001. ,
DOI : 10.1067/mcp.2001.118022
Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure, The Journal of Heart and Lung Transplantation, vol.22, issue.10, pp.1117-1125, 2003. ,
DOI : 10.1016/S1053-2498(02)01221-4
Everolimus in Pulmonary Transplantation: Pharmacokinetics and Exposure???Response Relationships, The Journal of Heart and Lung Transplantation, vol.25, issue.4, 2006. ,
DOI : 10.1016/j.healun.2005.12.001
Everolimus Exposure in Cardiac Transplant Recipients is Influenced by Concomitant Calcineurin Inhibitor, Therapeutic Drug Monitoring, vol.30, issue.1, pp.113-116, 2008. ,
DOI : 10.1097/FTD.0b013e318161a335
Effect of Rifampin on Apparent Clearance of Everolimus, Annals of Pharmacotherapy, vol.15, issue.6, pp.981-985, 2002. ,
DOI : 10.1345/aph.1A384
Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients, Pediatric Transplantation, vol.9, issue.Suppl. 2, pp.147-152, 2002. ,
DOI : 10.1034/j.1399-3046.2002.01070.x
Everolimus in pediatric de nova renal transplant patients1, Transplantation, vol.75, issue.12, pp.2082-2085, 2003. ,
DOI : 10.1097/01.TP.0000070139.63068.54
RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.20, issue.3, pp.330-339, 2001. ,
DOI : 10.1016/S1053-2498(00)00232-1
Clinical Experience With Certican?? (Everolimus) in Maintenance Heart Transplant Patients at the Medical University of Vienna, The Journal of Heart and Lung Transplantation, vol.24, issue.4, 2005. ,
DOI : 10.1016/j.healun.2005.01.021
Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure-Effect Modeling, American Journal of Transplantation, vol.3, issue.5, pp.2126-2131, 2004. ,
DOI : 10.1056/NEJMoa021744
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, Clinical Pharmacology & Therapeutics, vol.75, issue.5, pp.422-455, 2004. ,
DOI : 10.1016/j.clpt.2004.01.009
Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine???sirolimus interaction, Kidney International, vol.70, issue.6, pp.1019-1025, 2006. ,
DOI : 10.1038/sj.ki.5001649
Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model, Transplantation Proceedings, vol.30, issue.5, pp.2200-2203, 1998. ,
DOI : 10.1016/S0041-1345(98)00590-9
SDZ RAD inhibits cold ischemia-induced vascular remodeling, Transplantation Proceedings, vol.31, issue.1-2, pp.1024-1025, 1999. ,
DOI : 10.1016/S0041-1345(98)01885-5
-(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats, American Journal of Respiratory and Critical Care Medicine, vol.163, issue.2, pp.498-502, 2001. ,
DOI : 10.1164/ajrccm.163.2.2006093
Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis, The Journal of Heart and Lung Transplantation, vol.26, issue.6, pp.584-592, 2007. ,
DOI : 10.1016/j.healun.2007.03.005
Benefit of a 50% Reduction of Cyclosporine Exposure in Stable Kidney Transplant Recipients Treated with MMF without Corticosteroids. The DICAM Randomized Study, Am J Transplant, vol.7, issue.52, p.207, 2007. ,
Therapeutic drug monitoring (TDM) of prednisolone in lung transplantation, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.192, 2001. ,
DOI : 10.1016/S1053-2498(00)00402-2
Simultaneous Determination of Plasma Prednisolone, Prednisone, and Cortisol Levels by High-Performance Liquid Chromatography, Therapeutic Drug Monitoring, vol.23, issue.2, pp.163-168, 2001. ,
DOI : 10.1097/00007691-200104000-00012
Pre-Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation, American Journal of Transplantation, vol.18, issue.4 ,
DOI : 10.1097/01.TP.0000062833.14843.4B
IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients, Clinical Pharmacology & Therapeutics, vol.10, issue.5, pp.711-717, 2008. ,
DOI : 10.1038/sj.clpt.6100347
ASSOCIATION OF CYTOKINE POLYMORPHIC INHERITANCE AND IN VITRO CYTOKINE PRODUCTION IN ANTI-CD3/CD28-STIMULATED PERIPHERAL BLOOD LYMPHOCYTES1, Transplantation, vol.72, issue.8, pp.1444-1450, 2001. ,
DOI : 10.1097/00007890-200110270-00019
THE VALUE OF POSTTRANSPLANT MONITORING OF INTERLEUKIN (IL)-2, IL-3, IL-4, IL-6, IL-8, AND SOLUBLE CD23 IN THE PLASMA OF RENAL ALLOGRAFT RECIPIENTS, Transplantation, vol.59, issue.3, pp.333-340, 1995. ,
DOI : 10.1097/00007890-199502000-00005
SPARSE SAMPLE MEASUREMENT OF CYCLOSPORIN AUC AFTER NEORAL?? IN HEART TRANSPLANT PATIENTS., Therapeutic Drug Monitoring, vol.21, issue.4, p.447, 1999. ,
DOI : 10.1097/00007691-199908000-00086
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*, Clinical Pharmacology & Therapeutics, vol.33, issue.6, pp.672-683, 1998. ,
DOI : 10.1016/S0009-9236(98)90058-3